China News Service, September 30. On September 27, the Fifth China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as the "Venture Investment Conference") was held in Suzhou Industrial Park. This conference is co-sponsored by the China Association for the Promotion of Pharmaceutical Innovation (hereinafter referred to as "China Association for the Promotion of Pharmaceuticals"), China Medical Device Industry Association, Hong Kong Stock Exchange, and IMD Consulting. The conference attracted nearly 2,000 people from more than 100 representatives from domestic and foreign investment institutions, pharmaceutical innovation companies, and research institutes.
Song Ruilin, Executive Chairman of China Pharmaceutical Innovation Promotion Association
This year's Venture Capital Conference implements the purpose of "promoting the integration of domestic and foreign social capital and pharmaceutical innovation, and improving the innovation capabilities of my country's pharmaceutical industry". in-depth discussions on the development direction of China's pharmaceutical innovation and investment and financing in the post-epidemic era, and show the world China's pharmaceutical innovation The strong driving force of the company. build a high-end dialogue and cooperation platform for efficient communication and matching precision for domestic and foreign pharmaceutical innovation projects, scientists, and investors.
Ren Jinsheng, the annual president of the China Association for the Promotion of Pharmaceutical Innovation, said in his speech that 2020 is an extremely extraordinary year. The new crown epidemic has a profound impact on the global economy. China's biomedical industry is facing uncertainty and an unprecedented series of challenges. The next five years will be a key opportunity period for the transformation and upgrading of China’s biomedicine. China’s pharmaceutical innovation and investment should not only pay attention to the internal circulation of market and resource elements, but also make good use of Chinese elements and advantages, vigorously promote foreign exchanges and cooperation, and use openness. And cooperate to promote pharmaceutical innovation and investment. Contribute Chinese forces to innovation and investment in the global life sciences.
Due to the epidemic, Hong Kong Stock Exchange President Li Xiaojia could not be there in person. He sent a speech via online video. President Li Xiaojia said that currently, there are a total of 154 various health and pharmaceutical companies listed in Hong Kong, reaching a market value of 2.600 billion. Among these 154 companies, 20 biotech companies are listed under Chapter 18A of the Listing Rules. The Hong Kong Stock Exchange uses market principles, market rules, and market supply and demand to determine the frequency, timing and various rules of listing, gradually making the market more and more mature. The improvement of the ecosystem requires everyone to work together. As an important global financing platform, the Hong Kong Stock Exchange strives to become a booster for the biotechnology and pharmaceutical industries and promote industrial development.
"Research on China's Most Valuable Biomedical Innovation City for Investment" project released
Chen Deming, president of the China Association of Enterprises with Foreign Investment, said in his speech that foreign-funded pharmaceutical companies are a member of the big family of Chinese pharmaceutical companies and should be responsible for participating in China's pharmaceutical innovation and investment. From a practical point of view, the products and services of foreign-funded pharmaceutical companies generally have a high level of research and development, strict quality control, and good efficacy. They themselves are one of the representatives and leaders of innovation and investment. Foreign-funded pharmaceutical companies should actively integrate into and actively serve China's public health cause. This year, in the context of the global fight against the epidemic, the Chinese government has included biomedicine in China's pillar industry for the first time, comprehensively enhancing the innovation and development capabilities of the biomedical industry. Foreign pharmaceutical companies are willing to do their utmost for the innovation and investment of biomedicine. It is hoped that foreign-funded pharmaceutical companies can continue to unite and cooperate with domestic and foreign counterparts in research and development, and continue to contribute to the health of the Chinese people.
At the meeting, the "Research on China's Most Valuable Biomedical Innovation Cities" project was released. The list of "China's Most Valuable Biomedical Innovation Cities" was also announced for the first time at this forum. Shanghai, Beijing, Guangzhou, Suzhou, Shenzhen, Tianjin, Ten major cities including Nanjing, Chengdu, Wuhan, and Chongqing are among the best, leading the country.
"With the continuous improvement of China's pharmaceutical innovation environment, my country has moved from the third-party array of global pharmaceutical innovation to the second square. In this process, we first felt the government's high support for the pharmaceutical industry. The homogeneity of the park and the mutual imitation and reorganization are becoming more and more serious." President Song Ruilin said that the medical innovation city development forum and the project of "China's most investment-worthy biomedical innovation city research" are aimed at using an international perspective and Experience has made a standard of measurement, so that city builders can know more clearly what essential elements a well-developed park relies on.
"From the experience of Chinese and foreign urban industrial development factors, the development of the bio-industry mainly consists of six elements, forming a'paper clip' system. The ranking of China's most investment-worthy biomedical innovation cities is based on the China Biomedical Innovation Index, which , Policy guarantee, R&D resources, innovation system, capital system, and corporate capabilities. Overall, the development of national infrastructure and policy guarantee is relatively comprehensive, and there is an initial trend of normal distribution, while R&D resources In terms of accumulation, innovation system construction, capital system and corporate capabilities, the development of cities across the country is uneven. Except for Shanghai and Beijing, other cities ranked at the top of the index have their own advantages in different fields." Such as Song Ruilin, Executive Chairman of China Pharmaceutical Innovation Promotion Association Say.
It is understood that the Venture Capital Conference has been successfully held five times since 2016. It is known as the most watched annual pharmaceutical investment event in the Asia-Pacific region and is highly recognized and widely praised by the pharmaceutical and investment communities. It has gradually become an authoritative and diversified achievement transformation and authoritative cooperation and exchange platform with extensive international influence, authority and diversification for interpreting Chinese medicine and investment and financing policies, displaying domestic and foreign pharmaceutical innovation achievements and leading new investment trends.
The conference promoted the in-depth cooperation between global capital and my country's pharmaceutical innovation under the new crown epidemic, and deepened the global capital and pharmaceutical innovation industry’s understanding of my country and the global pharmaceutical innovation development trend, pharmaceutical innovation investment and financing, and fully released and promoted the vitality of pharmaceutical innovation. Contributions to the timely and efficient transformation of innovation results will also have a more positive and important impact on promoting the transformation and upgrading and innovative development of my country's pharmaceutical industry. To promote the transformation of the pharmaceutical industry from imitation to innovation, to meet the needs of clinical medication, and to contribute to a healthy China.